Cardiovascular nanoimmunotherapy
Immunomodulation therapies to tackle the most prominent range of clinical ailments
Atherosclerosis, a chronic disease of the large arteries, is one key underlying cause of myocardial infarction and stroke. Driven by cholesterol accumulation and subsequent inflammation in the vessel wall, atherosclerosis has historically been clinically treated by lipid-lowering treatments but remains a major threat to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have opened up a range of potential therapeutic targets to reduce the risk of cardiovascular disease, which has shifted the focus from lipids to inflammation. Our lab has pioneered nanotechnology approaches to facilitate the specific targeting of innate immune cells. With continued research efforts focusing on this crucial and promising field, we believe our approaches can generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. 
Mark IVIS.png